Abasi Ene-Obong, the former CEO of 54gene, has revealed his latest project, Syndicate Bio. Ene-Obong has kept this venture under wraps for several months, and now it's making headlines.
In a nutshell, Syndicate Bio aims to advance genomics and precision medicine on a global scale. Ene-Obong is starting this journey with a focus on Africa, collaborating with governments, pharmaceutical companies, academic institutions, and other partners to drive local precision medicine efforts. They're also gathering valuable data to aid in the development of new drugs.
Ene-Obong has a track record of supporting African scientists. During his time at 54Gene, he provided scholarships to four African doctoral candidates, furthering genomics research on the continent. He's committed to continuing this mission with Syndicate Bio.
His departure from 54Gene raised questions, with some speculating about financial misconduct. However, no allegations have been proven. His exit coincided with challenges faced by 54Gene, including economic difficulties that led to layoffs.
Despite the challenges, 54gene has raised significant funding, around $45 million, and remains valued at over $150 million. Ene-Obong's new venture, Syndicate Bio, is poised to make a substantial impact on the genomics field, not only in Africa but globally.
No comments